Evidence map›Paper›PMID 39596137›Full record

ReviewInternational journal of molecular sciences2024

Determinants of Photodynamic Therapy Resistance in Cancer Cells.

Alicja Dąbrowska, Jakub Mastalerz, Bartosz Wilczyński, Beata Osiecka, Anna Choromańska

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Alicja DąbrowskaFaculty of Medicine, Wroclaw Medical University, Pasteura 1, 50-367 Wroclaw, Poland.ORCID 0000-0001-8610-107X
Jakub MastalerzFaculty of Medicine, Wroclaw Medical University, Pasteura 1, 50-367 Wroclaw, Poland.ORCID 0009-0007-1974-149X
Bartosz WilczyńskiFaculty of Medicine, Wroclaw Medical University, Pasteura 1, 50-367 Wroclaw, Poland.ORCID 0000-0002-9624-6309
Beata OsieckaDepartment of Clinical and Experimental Pathology, Wroclaw Medical University, T. Marcinkowskiego 1, 50-368 Wroclaw, Poland.
Anna ChoromańskaDepartment of Molecular and Cellular Biology, Wroclaw Medical University, Borowska 211A, 50-556 Wroclaw, Poland.ORCID 0000-0001-9997-7783

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Photodynamic therapy (PDT) has emerged as a promising therapeutic approach owing to its non-invasive nature and minimal toxicity. PDT involves the administration of a photosensitizing agent (PS), which, upon light activation, induces a photodynamic reaction (PDR), leading to targeted cell destruction. However, developing resistance to PDT poses a significant challenge to its effectiveness. Various factors, including properties and administration of PSs, mediate this resistance. Despite the widespread use of substances like 5-aminolevulinic acid (5-ALA) and protoporphyrin, their efficacy is limited due to restricted tumor penetration and a lack of tumor targeting. To address these limitations, nano-delivery techniques and newer PSs like Aza-BODIPY and its derivatives, which offer enhanced tissue penetration, are being explored. In this paper, we provide an overview of resistance mechanisms in PDT and discuss novel methods, substances, and technologies to overcome resistance to improve clinical outcomes in tumor treatment.

Indexed as

Drug Resistance, NeoplasmNeoplasmsPhotochemotherapyPhotosensitizing AgentsAminolevulinic AcidAnimalsHumansAminolevulinic AcidPhotosensitizing Agentsdrug resistancephotochemotherapyphotosensitizing agents

Identifiers

PMID39596137
PMCPMC11594179

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.